Strata Skin Sciences ( (SSKN) ) has released its Q3 earnings. Here is a breakdown of the information Strata Skin Sciences presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
STRATA Skin Sciences, Inc. is a medical technology company that specializes in developing and marketing innovative products for the treatment of dermatologic conditions, focusing on in-office solutions for conditions such as psoriasis, vitiligo, and acne.
In its third-quarter 2025 earnings report, STRATA Skin Sciences highlighted significant progress in expanding reimbursement codes for skin disease treatments, regulatory clearance in Mexico for its TheraClearX device, and new clinical validations for its XTRAC laser treatments. Despite these advancements, the company reported a decline in total revenue due to international market challenges.
Key financial metrics for the quarter included a slight positive EBITDA compared to a negative figure in the previous year, an 8.5% increase in average gross billings per device, and a gross margin of 60%. However, total revenue decreased by 21% year-over-year, primarily due to a 60% drop in equipment revenue, while global recurring revenue saw a modest 3% increase. The company also reported a net loss of $1.6 million, an improvement from the $2.1 million loss in the same period last year.
The company is optimistic about future growth, driven by the newly approved reimbursement codes and positive litigation outcomes, which are expected to attract new customers and increase revenue. STRATA continues to focus on cost management and strategic expansion of its patient base through direct-to-consumer efforts and support for its clinical partners.
Looking ahead, STRATA Skin Sciences remains committed to refining its business model and expanding its market presence, with a focus on leveraging new reimbursement opportunities and strengthening its partnerships with clinicians to drive future growth.